Navigation Links
ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
Date:2/25/2009

HALIFAX, NS, Feb. 25 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has signed a collaborative agreement with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in Maryland, USA. The research collaboration involves formulating NIAID antigens in DepoVax(TM), IVT's vaccine enhancement system, and exploring potential vaccines for HIV and malaria.

"NIAID is a world leader in the study of infectious and immune-mediated disease, and we look forward to seeing how our enhanced DepoVax(TM) delivery system augments this research," said Dr. Marc Mansour, vice president of R&D at IVT.

There are currently a limited number of vaccine formulations capable of inducing potent and durable T cell responses. Several vaccines in development, based on replication-defective adenovirus, are limited in their ability to be used repeatedly. There is an urgent need to develop protein vaccines that can induce antibody and T cell responses, and be used in combination with other vaccines. The goal of this pre-clinical research collaboration is to establish whether a novel vaccine formulation, in which a specified protein is formulated in DepoVax(TM), will induce stronger T cell responses compared to other protein-based formulations. Proteins from HIV, SIV and malaria will be tested.

ABOUT IVT

ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a privately held, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

www.immunovaccine.com.

ABOUT NIAID and NIH

NIAID conducts and supports research-on the NIH campus, throughout the United States, and worldwide-to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. www.niaid.nih.gov. The National Institutes of Health (NIH)-The Nation's Medical Research Agency-includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. www.nih.gov.


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
2. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
3. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
4. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
5. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
6. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
7. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
8. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
9. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
10. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
11. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative Radiology Solutions, ... and current participant in the Phase 1 Ventures program, is leveraging regional and ... Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying medical imaging ...
(Date:6/22/2016)... ... 22, 2016 , ... The Immigrant Journey Awards , ... to North Texas and the nation, recently held its annual luncheon program. ... civic and economic vitality of North Texas. Proceeds from the event are used ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):